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INTRODUCTION
In anti-cancer therapy many efforts are made to detect response or resistance to treatment at an early time point. This enables an early shift of the therapy regimen, which allows for reduction of side effects, an optimized therapy for the patient, and a reduction of costs for the health care system. Molecular imaging is a valuable tool to non-invasively and longitudinally follow biological and molecular processes within the body. In tumors, these processes may shed light on therapy response. Consequently, use of appropriate imaging biomarkers might help to evaluate anti-cancer therapies in clinical trials. Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a chemotherapeutic agent employed in e.g. lung (6) or pancreatic cancer (7) . It exerts an anti-cancer effect 5 mostly by interfering with DNA synthesis. Its metabolites can be incorporated into DNA, thereby abrogating effective DNA synthesis. Furthermore, it inhibits thymidylate synthase (TS), the key enzyme of the thymidine de novo synthesis pathway (8, 9 
MATERIALS AND METHODS

Cell culture experiments
A549 (DSMZ) and H1975 (LGC standards, both obtained in 12/2011) non-small cell lung cancer cells were cultured at 37 °C in 5 % CO2 with DMEM or RPMI, respectively, containing 10 % fetal calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin. Cell line identity was confirmed by the supplier by short tandem repeat analysis and cells were used at early passage. An MTT assay (Sigma, M5655) was performed according to the manufacturer's protocol to determine cell viability after gemcitabine administration. Cells were incubated for 48 h with different concentrations of gemcitabine (0.01 µM -10 µM, Gemzar, Eli Lilly, obtained from the pharmacy of the University Hospital Münster). Tracer uptake was determined as described above.
Western blot
Cells were lysed in RIPA and subjected to polyacrylamide gel electrophoresis. After transfer to a PVDF membrane, proteins were probed with antibodies targeting TK1 (Abcam, EPR3193, 1:1000) or actin (MP Biomedicals, clone C4, 69100, 1:1000).
Secondary antibodies were coupled with peroxidase, and signals were visualized with Pierce ECL Plus Western Blotting Substrate (Pierce Biotechnology).
Densitometry analysis of bands was performed with ImageJ and plotted relative to actin loading control. TK1 expression levels were normalized to the expression of NaCl treated control cells on the same blot.
Animal Model
Animal procedures were performed within the multi-center QuIC-ConCePT study in accordance with the German Laws for Animal Protection and were approved by the animal care committee of the local government (North Rhine-Westphalia State Agency for Nature, Environment and Consumer Protection). During the experiments general health and body weight of the mice were monitored. 6-8 week old female NMRI nude mice (Janvier Labs) were used for the experiments. Three tumors per mouse were inoculated subcutaneously in the shoulder region by injection of 2 x 10 6 cells in 50 µL medium. Tumor volumes were calculated from digital caliper
Mice were treated by intraperitoneal injection of 100 mg/kg gemcitabine in 100 µL 0.9 % NaCl at 3 d intervals or 0.9 % NaCl as control. Imaging was performed according to the experimental schedule depicted in Supplementary Fig. S1 .
PET imaging
[ 18 F]FLT was produced with purity of >99 % as reported previously (12) . Mice were anesthetized with isoflurane inhalation (2 % in oxygen), and temperature was maintained at 37 °C by using a heating pad. 10 MBq of radiotracer were injected intravenously and image acquisition was performed for 20 min after a 70 min tracer uptake period using a quadHIDAC small animal PET scanner (Oxford Positron Systems (13)). A multimodal bed was used to enable co-registration of PET images with anatomical images from CT (Inveon, Siemens Medical Solutions) or T2w MRI.
Images were analyzed with the software Inveon Research Workplace 3.0 (Siemens Medical Solutions). Three-dimensional volumes-of-interest (VOIs) were defined on CT or MR images over the entire tumor. Radiotracer uptake was calculated as maximal percentage injected dose per mL (%IDmax/mL). In addition, we also determined %IDmean/mL, standardized uptake value (SUVmax, SUVmean), and maximal tumor-to-musclemean and tumor-to-livermean-ratio. Results of the mean tumor uptake were substantially influenced by necrosis within the tumors. We also assessed the 25%ile, representing the mean of the 25% highest intensity voxels. All additional evaluations are listed in Supplementary Table S1 , and were used to demonstrate that findings were independent of the mode of data analysis To evaluate relative excretion, the radioactivity within the bladder VOI (%IDmean/mL) was multiplied by the volume of the VOI and divided by the total radioactivity within the mouse. 
Thymidine and gemcitabine quantification
Thymidine was analyzed with a modified liquid-chromatography-mass spectrometry (LC-MS/MS) method as described previously (14) . Gemcitabine LC-MS/MS was performed according to Bapiro et al. (15) .
Statistics
Data are displayed as box plots showing median values with 25 % and 75 % percentiles, with whiskers from minimum to maximum. Means ± standard deviation are listed in the Supplementary Table S2 . The numbers in brackets indicate the number of samples analyzed. SigmaPlot 13.0 was used for statistical analyses. Since not all data followed a normal distribution the Mann-Whitney Rank Sum Test was applied for comparisons. IC50 values were determined using the standard curve macro. Correlations were calculated with the Pearson method. P values < 0.05 were considered statistically significant.
RESULTS
Incubation of H1975 or A549 tumor cells with gemcitabine results in cell death and induction of increased [ 18 F]FLT uptake in vitro
We previously determined that H1975 and A549 lung cancer xenografts accumulate (Fig. 1B) , which was accompanied by reduced tracer uptake in this experimental setup. Gemcitabine incubation was accompanied by increased TK1 expression as determined by western blot (Fig. 1C) .
Thus, a TK1-associated increase in [ 18 F]FLT uptake was noted in both cell lines within 24 h, followed by a drug-dose dependent decrease in A549 cells.
In vivo growth of H1975 is affected by gemcitabine therapy whereas A549 growth is unaltered
We gave four doses of 100 mg/kg gemcitabine to nude mice bearing subcutaneous H1975 or A549 xenografts of a size of about 100 mm 3 . A549 xenografts grew substantially more slowly. There was no evidence of gemcitabine-induced toxicity. A growth inhibitory effect was observed from d5 onwards for H1975 xenografts ( Fig. 2A) , whereas growth of A549 was unaffected (Fig. 2B) . Thus, a gemcitabine-responsive and a non-responsive model were available to evaluate the ability of 
Gemcitabine affects [ 18 F]FLT uptake in both models in vivo
We performed [ 18 F]FLT PET imaging at various time points after administration of gemcitabine (Fig. 3) . In both tumor types tracer uptake was significantly reduced within hours after drug application and significantly increased on d1 (%IDmax/mL of H1975: baseline: 18.6 ± 3.3, 6 h: 9.8 ± 2.0, P < 0.001; d1: 21.5 ± 3.2, P < 0.01; A549: baseline: 6.39 ± 1.57, 6 h: 3.68 ± 0.68, P < 0.001; d1: 8.95 ± 2.75, P < 0.001, significances relative to baseline, see Supplementary Table S2 Supplementary Table S1 ).
We analyzed Ki67 immunohistochemistry to assess whether [ 18 F]FLT accumulation reflects cellular proliferation. In both tumor models, Ki67 was unchanged after gemcitabine therapy (Fig. 4 and Supplementary Fig.S2 ). Unaltered [ 18 F]FLT on d2 and d3 was in accordance with unchanged cellular proliferation as determined by Ki67 immunohistochemistry. The cause for the above described changes in [ 18 F]FLT uptake (i.e. decrease after 6 h, increase after 1 d, and decrease after 5 d in H1975 xenografts) appeared to be unrelated to this proliferation marker.
Immunohistochemical analysis revealed an increased TK1 expression on d1 after gemcitabine (% positive area of H1975: NaCl: 21.5 ± 5.0, d1: 45.1 ± 8.8; A549: NaCl:
19.9 ± 5.8, d1: 36.8 ± 4.3; both P < 0.01 relative to NaCl control). A significant positive correlation of TK1 expression and [ 18 F]FLT uptake was measured in both models (Fig. 5) . Of note, for the H1975 tumors, PET imaging after 6 h was only performed in longitudinal studies. Hence, immunohistochemistry at this time point was conducted in a different cohort of mice, not allowing direct correlation analysis of this time point. For consistency, we did not plot this time point for A549 either; however, inclusion of these 6 h data also results in a significant correlation of [ 18 F]FLT uptake and TK1 expression (r = 0.539, P < 0.01).
[ 18 F]FLT uptake after 6 h in tumors was low although TK1 expression was elevated. Fig. S3 ). Interestingly, not only tumor uptake was reduced at this time point but [ 18 F]FLT retention in a range of other organs was also diminished (e.g. spleen, muscle or lymph nodes, see Supplementary Table S3) , indicating a potential systemic rather than a tumorspecific effect. Gemcitabine, being a nucleoside analog, employs cellular transport mechanisms similar to the ones used by [ 18 F]FLT and thymidine. Hence, we hypothesized that high gemcitabine concentrations in the plasma compete with We showed that less [ 18 F]FLT is taken up by cells in the presence of gemcitabine in vitro (Fig. 6A) , confirming the competitive nature of these two molecules. In vivo, LC-MS/MS analysis revealed gemcitabine (dFdC) tumor concentrations of 3.38 µM ± 2.34 µM in H1975 (n = 4) and ~1.2 µM in A549 (n = 2) and plasma concentrations in the range of 0.16 µM ± 0.08 µM (n = 5) 6 h after drug administration. The latter is well above concentrations estimated for [ 18 13.7 ± 5.8, 6 h: 24.8 ± 6.5, P < 0.05, Fig. 6B ). Thymidine also employs the cellular uptake mechanism for nucleosides. Plasma concentration of thymidine was significantly higher at 6 h (Fig. 6C) . Based on its short half-life (~30 min (17,18) ), plasma gemcitabine concentrations should be in the range of ~500 µM immediately after drug administration. This ~500-fold excess of gemcitabine over plasma thymidine suggests that increased thymidine concentrations after 6 h result from competition with gemcitabine. At later time points, plasma thymidine levels were significantly reduced relative to NaCl control whereas thymidine concentrations within H1975 tumors were increased (Fig. 6D) .
Also TS or human equilibrative nucleoside transporter 1 (hENT1) expression analysis did not explain reduced [ 18 F]FLT (Supplementary
ADC is slightly altered early after gemcitabine administration
We also determined whether gemcitabine application causes changes in the apparent diffusion coefficient (ADC), the measure for water diffusivity as determined by DW-MRI. Fig. 7A shows that ADCmean did not vary substantially on d1 or d2 after treatment in H1975 xenografts. In A549 tumors a small increase in ADC relative to baseline was detected, which was independent of treatment. This increase was more pronounced 1 d after gemcitabine. However, in both models, cellular density (Fig. 7B) and cell death (cleaved caspase-3 immunohistochemistry, Supplementary   Fig. S4) were not altered at these time points.
DISCUSSION
We employed two lung cancer models to investigate the effect of gemcitabine on There is a range of studies describing the successful use of [ 18 F]FLT PET for predicting response to anti-cancer agents (19, 20) . When employing agents interfering with TS activity, like 5-FU, an increase in [ 18 F]FLT uptake early after drug administration was frequently reported. This effect has been attributed either to upregulation of TK1 activity (10, 11) or to redistribution of hENT1 to the cellular surface (21) .
Gemcitabine also inhibits TS activity (8) . Consequentially, we also observed an [ 18 F]FLT increase both in vitro (Fig. 1) and in vivo (Fig. 3) . This is in accordance with an in vitro study that reported a 5-fold increase of [ 18 F]FLT 24 h after treatment with gemcitabine in oesophageal squamous cell carcinoma cells (22) . In our models, we showed that increased [ 18 F]FLT was related to TK1 expression (Fig. 1C and Fig. 5 ).
We noted a substantial decrease of tumor [ 18 F]FLT accumulation 6 h after gemcitabine administration (Fig. 3) (Fig. 6A) . Both molecules share cellular uptake mechanisms, and the major transporter is presumably hENT1. We determined gemcitabine plasma concentrations to be ~160 nM about 6 h after drug application. This is in good agreement with previously published gemcitabine concentrations (15, 27 (Fig. 6B) . One might speculate that such a systemic effect on tracer uptake calls for correction of [ 18 F]FLT uptake to an internal reference tissue.
But after also correcting for muscle or liver uptake, the relative decrease in tumor Table S1 ). This implies that gemcitabine is preferentially taken up in tumors, in agreement with a study demonstrating a 3.5-fold increased accumulation of gemcitabine relative to liver (18) .
Hence, there are multiple pieces of evidence that support the hypothesis that 6 h after administration gemcitabine competes with [ 18 F]FLT for cellular uptake.
We also observed competition of gemcitabine with plasma thymidine 6 h after drug administration (Fig. 6C) . d1, d2 and d3 after gemcitabine, plasma thymidine concentrations were reduced relative to the NaCl control. This is in line with other studies employing TS-inhibiting agents which showed reduced thymidine levels in plasma in mice (29) and men (30), presumably originating from the drug induced blockade of the de novo pathway and increased use of the salvage pathway and hence extracellular thymidine. A significant increase in thymidine concentration was noted in H1975 xenografts. This could possibly be caused by an accumulation of phosphorylated thymidine within the cells, which cannot be incorporated into the DNA since gemcitabine inhibits DNA synthesis. The fact that this increase in thymidine cannot be detected in A549 xenografts, whose growth is not impaired after gemcitabine treatment, supports this hypothesis.
Of note, changes in [ 18 F]FLT uptake and TK1 expression within the first days were observed in both tumor models investigated, even though they substantially differed with respect to sensitivity to gemcitabine (Fig. 2) . Gemcitabine concentrations within A549 tumors were in a similar range to those in H1975 tumors, demonstrating that gemcitabine is capable of entering these cells. A double dose of gemcitabine did cause a reduction in tumor volume in a small cohort of mice (Supplementary Fig.   S5 ). Hence, as previously reported (31, 32) , A549 xenografts were not intrinsically resistant to this drug, but in our study the dose used was sub-therapeutic.
Consequently, the observed early changes in [ 18 F]FLT uptake (reduction after 6 h and increase after 1 d) were not related to treatment response. This is in accordance with studies showing that sub-therapeutic doses of TS inhibiting agents induce an [ 18 F]FLT increase in vitro (33) and in vivo (34) .
A growth inhibition-related decrease in [ 18 F]FLT uptake was only seen on d5 of gemcitabine therapy. Presumably, this was related to increased apoptosis as determined by immunohistochemistry of cleaved caspase-3 (Supplementary Fig. S4 ). In our study, H1975 tumor volumes between the treated and the untreated groups were already significantly different on d5. Hence, molecular imaging with DW-MRI is an alternative imaging approach to monitor cancer therapy, as has been shown e.g. for experimental Ewing sarcoma (35) . We were unable to detect any substantial differences in tumor ADCmean 1 d or 2 d after a single dose of gemcitabine in either of the lung tumor models investigated here (Fig. 7A) . This was in accordance with unchanged cellular density and cell death. The slight increase in ADC in A549 xenografts most likely resulted from other structural changes such as a growth-related increase in necrosis, which was irrespective of treatment. These observations emphasize that ADC is a versatile measure that is influenced by a complex combination of parameters related to tissue micro-structure. Transient effects such as cell swelling or shrinkage possibly overshadow changes of parameters that can be related to therapy with our current knowledge. Hence, in our model ADC had no predictive value.
In conclusion, our data demonstrate that plasma levels of gemcitabine alter nucleoside transporter availability and hence [ 18 xenografts. Tumor volumes were determined by caliper measurements and showed a growth inhibitory effect of gemcitabine (given on d0, d3, d6, and d9) in H1975 but not in A549 tumors. White: NaCl; grey: gemcitabine; *: P < 0.05, **: P < 0.01, ***: P < 0.001 relative to NaCl. Hence, the images from d5 depict different tumors. Scale bar = 5 mm; white: NaCl; grey: gemcitabine; *: P < 0.05, **: P < 0.01, ***: P < 0.001 relative to NaCl; † : P < 0.05, † † : P < 0.01; † † † : P < 0.001 relative to baseline. 
